• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    6/6/22 5:51:15 PM ET
    $ACET
    $ADTX
    $ATHX
    $BDSX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email

    Gainers

    • Vaxxinity (NASDAQ:VAXX) stock moved upwards by 10.2% to $3.56 during Monday's after-market session. The company's market cap stands at $448.5 million.
    • Delcath Systems (NASDAQ:DCTH) shares increased by 9.77% to $4.94. Trading volume for this security closed at 97.8K, accounting for 386.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $39.0 million.
    • Adicet Bio (NASDAQ:ACET) shares increased by 8.38% to $13.29. The company's market cap stands at $531.5 million.
    • First Wave BioPharma (NASDAQ:FWBI) stock increased by 6.72% to $0.31. The company's market cap stands at $6.6 million.
    • Recursion Pharmaceuticals (NASDAQ:RXRX) shares rose 6.27% to $7.62. The market value of their outstanding shares is at $1.3 billion.
    • Zosano Pharma (NASDAQ:ZSAN) stock rose 6.17% to $0.6. This security traded at a volume of 132.4K shares come close, making up 1.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $2.9 million.

    Losers

    • Aditxt (NASDAQ:ADTX) shares fell 9.9% to $0.26 during Monday's after-market session. The company's market cap stands at $11.6 million.
    • Biodesix (NASDAQ:BDSX) shares decreased by 7.8% to $1.42. The market value of their outstanding shares is at $56.5 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) shares fell 6.68% to $0.53. At the close, Quoin Pharmaceuticals's trading volume reached 5.0 million shares. This is 798.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.3 million.
    • SCWorx (NASDAQ:WORX) stock declined by 6.05% to $0.7. The market value of their outstanding shares is at $7.9 million.
    • Athersys (NASDAQ:ATHX) shares decreased by 5.22% to $0.29. Today's trading volume for this security ended up closing at 397.9K shares, which is 8.4 percent of its average volume over the last 100 days. The company's market cap stands at $74.0 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares decreased by 4.9% to $0.35. The company's market cap stands at $4.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACET
    $ADTX
    $ATHX
    $BDSX

    CompanyDatePrice TargetRatingAnalyst
    Biodesix Inc.
    $BDSX
    2/27/2026Mkt Perform → Outperform
    William Blair
    Recursion Pharmaceuticals Inc.
    $RXRX
    12/17/2025$11.00Neutral → Overweight
    Analyst
    Recursion Pharmaceuticals Inc.
    $RXRX
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    Biodesix Inc.
    $BDSX
    5/14/2025Outperform → Mkt Perform
    William Blair
    Adicet Bio Inc.
    $ACET
    9/30/2024$7.00Buy
    Guggenheim
    Biodesix Inc.
    $BDSX
    9/16/2024Sector Outperform
    Scotiabank
    Adicet Bio Inc.
    $ACET
    9/11/2024Buy → Neutral
    H.C. Wainwright
    Biodesix Inc.
    $BDSX
    7/26/2024$3.00Buy
    Craig Hallum
    More analyst ratings

    $ACET
    $ADTX
    $ATHX
    $BDSX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

    NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a leading tech-bio company decoding biology through advanced data science and automation. Recursion's end-to-end platform is designed to connect discovery through development by integrating proprietary multimodal datasets, purpose-built AI models, and experimental biology. The addition of Citeline's real-world data and evidence capabilities strengthens this foundation, enabling more precise trial design, improved site selection, and faster, more informed development decisions

    3/31/26 9:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

    – Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe  – Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4 – Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile – Pediatric NS Study Expanded to 7 Children Now Actively Treated with QRX003, Largest Cohort of This Age Group Ever Studied – Ongoing Clinical Data Continues to Support Development of QR

    3/26/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

    FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront vehicle or placebo control Quoin remains on track to initiate a Phase 3 study and complete Phase 3 patient recruitment in 2026 and potentially file for NDA approval in 2027 ASHBURN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today provided a clinical and regulatory update from its recent constructive Type C meeting

    3/25/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix upgraded by William Blair

    William Blair upgraded Biodesix from Mkt Perform to Outperform

    2/27/26 8:20:07 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Recursion Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00

    12/17/25 8:47:25 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Recursion Pharmaceuticals with a new price target

    Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00

    7/3/25 7:50:07 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dar Zavain

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/2/26 4:56:26 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Li Dean Y

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/2/26 4:56:19 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Patience John

    4 - BIODESIX INC (0001439725) (Issuer)

    4/2/26 4:52:13 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Aditxt Inc.

    DEF 14A - Aditxt, Inc. (0001726711) (Filer)

    4/3/26 4:37:32 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Other Events

    8-K - Aditxt, Inc. (0001726711) (Filer)

    4/2/26 9:13:36 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Delcath Systems Inc.

    DEFA14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    4/2/26 8:55:31 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/6/26 4:22:21 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/3/26 4:15:22 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ACET
    $ADTX
    $ATHX
    $BDSX
    Financials

    Live finance-specific insights

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

    Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

    2/26/26 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively Gro

    2/26/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care